Researchers examine efficacy, safety of at-home abortion pills

A recent report by The New York Times follows the story of a woman who opted for a medicine-induced abortion in her home on her own terms.

“I was happy that I was going to be able to do it myself, and I did not have a nurse there or doctors there staring at me and judging me,” said Marie, identifying only by her middle name.

She is part of a research effort to examine how effective and safe a medicine induced abortion can be done through online consultations and drugs mailed to a patient’s home.

Though some find the concept dangerous and disturbing, other says it could be a good option for women at a time when access to abortion is limited.

To read more about the option, follow the link below.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

While Kardium raised $250 million in an oversubscribed funding round, Field Medical raised $35 million. Both companies are focused on designing and developing new pulsed field ablation technologies to help treat challenging arrhythmias. 

Johnson & Johnson MedTech has received reports of its Automated Impella Controller failing to connect properly with Impella heart pumps. If this happens, the FDA warned, it may put patients at risk.

Vascular Technology, first founded 40 years ago, is planning on using the new funds to grow and expand its portfolio.